301263 泰恩康
已收盘 10-13 15:00:00
资讯
新帖
简况
研报掘金丨东方证券：维持泰恩康“增持”评级，玫瑰痤疮信号积极，临床推进提速
格隆汇 · 10-12 13:21
研报掘金丨东方证券：维持泰恩康“增持”评级，玫瑰痤疮信号积极，临床推进提速
股市必读：泰恩康新发布《关于全资子公司收到地夸磷索钠滴眼液药品注册证书的公告》
证券之星 · 10-12 02:54
股市必读：泰恩康新发布《关于全资子公司收到地夸磷索钠滴眼液药品注册证书的公告》
公司问答丨泰恩康：员工持股计划锁定期届满不等于近期必然出售 目前暂无明确减持时间表
格隆汇 · 10-10
公司问答丨泰恩康：员工持股计划锁定期届满不等于近期必然出售 目前暂无明确减持时间表
泰恩康（301263）披露控股股东部分股份质押公告，10月09日股价上涨3.35%
证券之星 · 10-09
泰恩康（301263）披露控股股东部分股份质押公告，10月09日股价上涨3.35%
泰恩康最新公告：全资子公司收到地夸磷索钠滴眼液药品注册证书
证券之星 · 10-09
泰恩康最新公告：全资子公司收到地夸磷索钠滴眼液药品注册证书
泰恩康（301263）股东郑汉杰质押1500万股，占总股本2.94%
证券之星 · 10-08
泰恩康（301263）股东郑汉杰质押1500万股，占总股本2.94%
9月28日泰恩康跌5.10%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 09-28
9月28日泰恩康跌5.10%，前海开源优质龙头6个月持有混合A基金重仓该股
股市必读：泰恩康（301263）9月24日董秘有最新回复
证券之星 · 09-28
股市必读：泰恩康（301263）9月24日董秘有最新回复
9月24日泰恩康跌9.09%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 09-24
9月24日泰恩康跌9.09%，前海开源优质龙头6个月持有混合A基金重仓该股
泰恩康：预计于2026年10月27日披露《2026年三季度报告》
证券之星 · 09-24
泰恩康：预计于2026年10月27日披露《2026年三季度报告》
泰恩康（301263）9月23日主力资金净买入767.63万元
证券之星 · 09-24
泰恩康（301263）9月23日主力资金净买入767.63万元
泰恩康(301263.SZ)子公司CKBA乳膏玫瑰痤疮适应症获得IIa期临床试验研究初步分析结果
智通财经 · 09-23
泰恩康(301263.SZ)子公司CKBA乳膏玫瑰痤疮适应症获得IIa期临床试验研究初步分析结果
9月21日泰恩康涨8.92%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 09-21
9月21日泰恩康涨8.92%，前海开源优质龙头6个月持有混合A基金重仓该股
泰恩康：9月15日召开业绩说明会，投资者参与
证券之星 · 09-16
泰恩康：9月15日召开业绩说明会，投资者参与
泰恩康新提交“-”商标注册申请
证券之星 · 09-11
泰恩康新提交“-”商标注册申请
泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%
证券之星 · 09-02
泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%
泰恩康：和胃整肠丸自7月起开始国产化供货
证券之星 · 08-27
泰恩康：和胃整肠丸自7月起开始国产化供货
泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权
中金财经 · 08-24
泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权
股市必读：泰恩康（301263）8月21日董秘有最新回复
证券之星 · 08-24
股市必读：泰恩康（301263）8月21日董秘有最新回复
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
证券之星 · 08-20
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
加载更多
公司概况
公司名称：
广东泰恩康医药股份有限公司
所属行业：
批发业
上市日期：
2022-03-29
主营业务：
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。
发行价格：
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":18.45,"timestamp":1791875022000,"preClose":18.9,"halted":0,"volume":3004080,"delay":0,"changeRate":-0.0238,"floatShares":364000000,"shares":511000000,"eps":-0.0093,"marketStatus":"已收盘","change":-0.45,"latestTime":"10-13 15:00:00","open":18.72,"high":18.84,"low":18.31,"amount":55802000,"amplitude":0.028,"askPrice":18.46,"askSize":30,"bidPrice":18.45,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-0.0093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791941400000},"marketStatusCode":5,"adr":0,"adjPreClose":18.9,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":20.79,"lowLimit":17.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":510597000,"isCdr":false,"pbRate":5.85,"roa":"--","roe":"0.22%","epsLYR":0.07,"committee":0.79646,"marketValue":9421000000,"turnoverRate":0.0082,"status":1,"floatMarketCap":6721000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2674826267","title":"研报掘金丨东方证券：维持泰恩康“增持”评级，玫瑰痤疮信号积极，临床推进提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2674826267","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674826267?lang=zh_cn&edition=full","pubTime":"2026-10-12 13:21","pubTimestamp":1791782467,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0188","BK0183","BK0012","301263","600958","BK0250","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674084508","title":"股市必读：泰恩康新发布《关于全资子公司收到地夸磷索钠滴眼液药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674084508","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674084508?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:54","pubTimestamp":1791744852,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，泰恩康报收于19.14元，上涨3.35%，换手率1.26%，成交量4.6万手，成交额8637.09万元。公司公告汇总：全资子公司山东华铂凯盛收到地夸磷索钠滴眼液《药品注册证书》，规格为3%，批准文号国药准字H20266157。该药品适用于伴随泪液异常的角结膜上皮损伤的干眼患者，规格为3%，批准文号为国药准字H20266157。原研药由参天制药开发，商品名为“丽爱思”。2023年该药品全终端销售额达2.28亿元。目前国内已有46家企业取得该药品批件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674891646","title":"公司问答丨泰恩康：员工持股计划锁定期届满不等于近期必然出售 目前暂无明确减持时间表","url":"https://stock-news.laohu8.com/highlight/detail?id=2674891646","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674891646?lang=zh_cn&edition=full","pubTime":"2026-10-10 17:19","pubTimestamp":1791623952,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674519858","title":"泰恩康（301263）披露控股股东部分股份质押公告，10月09日股价上涨3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674519858","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674519858?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:45","pubTimestamp":1791539128,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于控股股东、实际控制人部分股份质押的公告》。公告显示，广东泰恩康医药股份有限公司控股股东、实际控制人郑汉杰先生于2026年10月8日将其持有的15,000,000股公司股份质押给国通信托有限公司，占其所持股份比例14.14%，占公司总股本比例2.94%，质押用途为个人资金需要。本次质押后，郑汉杰累计质押股份36,620,000股，占其持股比例34.53%。合计累计质押65,294,000股，占公司总股本比例12.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900028050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830586","title":"泰恩康最新公告：全资子公司收到地夸磷索钠滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830586","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830586?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:28","pubTimestamp":1791538116,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的地夸磷索钠滴眼液《药品注册证书》。地夸磷索钠滴眼液适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900026921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673765960","title":"泰恩康（301263）股东郑汉杰质押1500万股，占总股本2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673765960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673765960?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:30","pubTimestamp":1791455447,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康10月8日公开信息显示，股东郑汉杰向国通信托有限公司合计质押1500.0万股，占总股本2.94%。质押详情见下表：截止本公告日，股东郑汉杰已累计质押股份3662.0万股，占其持股总数的34.53%，股东孙伟文已累计质押股份2867.4万股，占其持股总数的36.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800026983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670923810","title":"9月28日泰恩康跌5.10%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670923810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670923810?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:59","pubTimestamp":1790585950,"startTime":"0","endTime":"0","summary":"证券之星消息，9月28日泰恩康跌5.10%，收盘报18.8元，换手率1.87%，成交量6.8万手，成交额1.29亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409982","title":"股市必读：泰恩康（301263）9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409982?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:43","pubTimestamp":1790530988,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，泰恩康报收于19.81元，下跌9.09%，换手率4.17%，成交量15.18万手，成交额3.07亿元。董秘最新回复投资者： 1、请公司能否提早安排发布下3季度经营情况？公司CKBA成人白癜风适应症目前已启动III期临床试验工作，CKBA乳膏治疗儿童白癜风适应症II期临床试验受试者招募和筛选工作正在推进。当日关注点交易信息汇总：9月24日主力资金净流入1118.76万元，游资资金净流入1585.16万元，散户资金净流出2703.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146307","title":"9月24日泰恩康跌9.09%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146307","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669146307?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:45","pubTimestamp":1790239524,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日泰恩康跌9.09%，收盘报19.81元，换手率4.17%，成交量15.18万手，成交额3.07亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669346811","title":"泰恩康：预计于2026年10月27日披露《2026年三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669346811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669346811?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:09","pubTimestamp":1790237357,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康09月24日在投资者关系平台上答复投资者关心的问题。泰恩康回复：尊敬的投资者朋友您好，公司预计于2026年10月27日披露《2026年三季度报告》，具体情况请您关注公司后续披露的相关公告。公司CKBA成人白癜风适应症目前已启动III期临床试验工作，CKBA乳膏治疗儿童白癜风适应症II期临床试验受试者招募和筛选工作正在推进。如有重大进展，公司将按照相关规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400025983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669301014","title":"泰恩康（301263）9月23日主力资金净买入767.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669301014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669301014?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:10","pubTimestamp":1790212221,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，泰恩康报收于21.79元，上涨2.54%，换手率1.77%，成交量6.44万手，成交额1.4亿元。近5日资金流向一览见下表：泰恩康融资融券信息显示，融资方面，当日融资买入977.19万元，融资偿还814.56万元，融资净买入162.63万元。泰恩康主营业务：代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400009021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810625","title":"泰恩康(301263.SZ)子公司CKBA乳膏玫瑰痤疮适应症获得IIa期临床试验研究初步分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810625","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669810625?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:13","pubTimestamp":1790151207,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康 发布公告，近日，公司控股子公司江苏博创园生物医药科技有限公司自主研发的1类创新药CKBA乳膏玫瑰痤疮适应症IIa期临床试验已于近日完成数据整理。前期基于IIa期积极有效的初步数据，公司已提前启动IIb期临床试验，并已于2026年9月初完成首例受试者入组，后续公司将进一步加快IIb/III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","301263","BMED","MDTX","IBBQ","BK0250","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159264","title":"9月21日泰恩康涨8.92%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159264?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:47","pubTimestamp":1789980472,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日泰恩康涨8.92%，收盘报21.0元，换手率2.82%，成交量10.27万手，成交额2.13亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667676206","title":"泰恩康：9月15日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667676206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667676206?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:04","pubTimestamp":1789524248,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月15日泰恩康发布公告称公司于2026年9月15日召开业绩说明会。本记录表如有涉及未来的计划、业绩预测等方面的前瞻性陈述内容，均不构成本公司对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600009347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666118505","title":"泰恩康新提交“-”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2666118505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666118505?lang=zh_cn&edition=full","pubTime":"2026-09-11 07:15","pubTimestamp":1789082115,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日广东泰恩康医药股份有限公司新提交“-”商标注册申请。商标申请详情如下：今年以来广东泰恩康医药股份有限公司新申请注册商标17件，截止目前公司共持有注册商标529件，另有115件商标尚在注册申请中。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了3051.88万元，同比减10.13%。通过天眼查大数据分析，广东泰恩康医药股份有限公司共对外投资了11家企业，参与招投标项目7次；财产线索方面有商标信息497条，专利信息5条，著作权信息3条；此外企业还拥有行政许可308个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100013377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381081","title":"泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381081","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664381081?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:37","pubTimestamp":1788359832,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，泰恩康报收于19.02元，较前一交易日下跌2.81%，最新总市值为97.12亿元。公司于2026年9月2日披露《关于回购公司股份的进展公告》。公告显示，广东泰恩康医药股份有限公司于2026年6月16日召开董事会，审议通过回购公司股份方案，拟使用自有及自筹资金通过集中竞价方式回购A股股份，用于维护公司价值及股东权益。本次回购符合相关法规及公司方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700360","title":"泰恩康：和胃整肠丸自7月起开始国产化供货","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700360?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:48","pubTimestamp":1787834897,"startTime":"0","endTime":"0","summary":"和胃整肠丸7月份开始供货，是否会对三季度业绩造成影响？和胃整肠丸是公司成熟胃药大品种，将为三季度带来积极的业绩增量贡献，具体销售情况请关注公司后续定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661099242","title":"泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=2661099242","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661099242?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:27","pubTimestamp":1787538424,"startTime":"0","endTime":"0","summary":"8月17日晚间，泰恩康对外发布签署《战略合作协议》的自愿性披露公告。公告显示，近日公司已与广东普罗凯融生物医药科技有限公司及其实际控制人签署了《战略合作协议》。在泰恩康按照《增资协议》约定足额支付增资认购款并完成本次股权投资交割的前提下，泰恩康将取得MSCohi-O镜片项目在中国区域的独家商业推广服务权益。企业方面表示，MSCohi-O镜片是全球首创眼科眼表干细胞创新疗法，适应症拓展空间巨大，符合未来治疗趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260824/32344313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661324575","title":"股市必读：泰恩康（301263）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2661324575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661324575?lang=zh_cn&edition=full","pubTime":"2026-08-24 04:07","pubTimestamp":1787515631,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，泰恩康报收于19.03元，下跌4.03%，换手率1.49%，成交量5.42万手，成交额1.04亿元。董秘最新回复投资者： 1、贵公司从3季度开始经营情况将逐步向好，但是从市场走势来看始终有资金不想贵公司股价上涨关键原因是没有利用好回购资金走出强势走势打出辨识度？当日关注点交易信息汇总：8月21日主力资金净流入334.24万元，占总成交额3.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288738","title":"泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288738","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660288738?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:55","pubTimestamp":1787219730,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称，公司全资子公司华铂凯盛收到国家药监局签发的《药物临床试验批准通知书》，同意注射用顺铂聚合物胶束单药在晚期恶性肿瘤中开展临床试验。该药品为化药2.2类，旨在降低顺铂毒副作用并实现被动靶向性。目前国内尚无该药品获注册批件，公司提示研发及上市存在不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000032566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791916026451,"stockEarnings":[{"period":"1week","weight":-0.0335},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.1172},{"period":"6month","weight":-0.2356},{"period":"1year","weight":-0.3132},{"period":"ytd","weight":-0.2348}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0628},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.0423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14676人(较上一季度增加12.93%)","perCapita":"24823股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"51059万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}